The Center for Genetic Engineering and Biotechnology (, CIGB) is a research institute in Havana, Cuba.
Founding
In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World. Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy. Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.
Activity
In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[1] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.[1]
As of 2017, CIGB had 1,600 employees and sold 21 products internationally.
As of 2020, CIGB had two joint ventures with China.[2]
It is responsible for creating the Abdala vaccine.[3][4][5]
The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.[6]
See also
- BioCubaFarma
- Center of Molecular Immunology
External links
References
- UA Health Sciences Researchers Look to Collaborate With Cuba on Diabetic Wound Therapy deptmedicine.arizona.edu, retrieved 2023-12-27^
- Helen Yaffe. We Are Cuba! How a Revolutionary People Have Survived in a Post-Soviet World Yale University Press, 2020^
- Cuba's COVID vaccine rivals BioNTech-Pfizer, Moderna DW.COM, 2021-06-27, retrieved 2021-06-28^
- ABDALA Clinical Study - Phase III rpcec.sld.cu, Registro Público Cubano de Ensayos Clínicos, retrieved March 22, 2021^
- ABDALA Clinical Study rpcec.sld.cu, Registro Público Cubano de Ensayos Clínicos, retrieved March 22, 2021^
- Liz Conde Sánchez. How is Mambisa progressing on the road to authorization as an anti-COVID-19 vaccine? en.granma.cu, 7 April 2022, retrieved 6 May 2022^